Patents by Inventor Michael Edward Griffith Boursnell
Michael Edward Griffith Boursnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7374768Abstract: A mutant virus for use as a vaccine for prophylaxis or therapy, wherein the genome of the virus is defective in respect of a gene essential for the production of infectious virus. In one aspect the mutant virus, e.g. a herpesvirus, e.g HSV-1 or HSV-2, is capable of protecting a susceptible species immunised therewith against infection by the corresponding wild-type virus. In another aspect, the mutant virus acts as a vector for an immunogenic protein derived from a pathogen, encoded by foreign DNA incorporated in the mutant virus. The mutant virus can be produced by a recombinant host cell which expresses a gene complementing the defect. The mutant virus can be infectious for the host to be protected, and the genetic defect can allow expression in the infected host of at least some of the viral genes, which can provoke a cell-mediated immune response. The defect can be in a glycoprotein gene such as gH.Type: GrantFiled: June 2, 1995Date of Patent: May 20, 2008Assignee: Xenova Research LimitedInventors: Stephen Charles Inglis, Michael Edward Griffith Boursnell, Anthony Charles Minson
-
Publication number: 20030083289Abstract: A process of treating a human or non-human animal cell to introduce heterologous genetic material into said cell and express said material in said cell, comprises (a) providing a recombinant herpesviral vector which is an attenuated or replication-defective and non-transforming mutant herpesvirus, and which carries heterologous genetic material, and (b) transducing human or non-human animal cells selected from: hemopoietic cells, malignant cells related to blood cells, and malignant or non-malignant CD34 + cells; by contacting said cells with said virus vector to transduce said cells and express said genetic material. Among applications of the technique is modification of hemopoietic cells by transfer of genes, e.g. to generate tumor immunogens from malignant cells.Type: ApplicationFiled: January 8, 2002Publication date: May 1, 2003Inventors: Michael Edward Griffith Boursnell, Malcolm Keith Brenner, Dagmar Dilloo, Stephen Charles Inglis
-
Patent number: 6541009Abstract: A mutant virus for use as a vaccine, wherein the genome of the virus is defective in respect of a gene essential for the production of infectious virus. In one aspect the mutant virus is capable of protecting a susceptible species immunized therewith against infection by the corresponding wild-type virus. In another aspect, the mutant virus acts as a vector for an immunogenic protein derived from a pathogen and which is encoded by foreign DNA incorporated in the mutant virus. The mutant virus can be produced in a recombinant host cell which expresses a gene complementing the defect. The mutant virus is preferably infectious for the host to be protected, but the defective gene allows expression in the infected host of at least some of the viral genes, which can provoke a cell-mediated immune response.Type: GrantFiled: June 5, 1995Date of Patent: April 1, 2003Assignee: Xenova Research LimitedInventors: Stephen Charles Inglis, Michael Edward Griffith Boursnell, Anthony Charles Minson
-
Patent number: 6344445Abstract: A process of treating a human or non-human animal cell to introduce heterologous genetic material into said cell and express said material in said cell, comprises (a) providing a recombinant herpesviral vector which is an attenuated or replication-defective and non-transforming mutant herpesvirus, and which carries heterologous genetic material, and (b) transducing human or non-human animal cells selected from: hemopoietic cells, malignant cells related to blood cells, and malignant or non-malignant CD34+cells; by contacting said cells with said virus vector to transduce said cells and express said genetic material. Among applications of the technique is modification of hemopoietic cells by transfer of genes, e.g. to generate tumor immunogens from malignant cells.Type: GrantFiled: October 18, 1996Date of Patent: February 5, 2002Assignees: Cantab Pharmaceutical Research Limited, St. Jude Children's Research HospitalInventors: Michael Edward Griffith Boursnell, Malcolm Keith Brenner, Dagmar Dilloo, Stephen Charles Inglis
-
Patent number: 5837261Abstract: The application provides a pharmaceutical which comprises a mutant non-retroviral virus (particularly HSV-1 and/or HSV-2) whose genome is defective in respect of a gene essential for the production of infectious virus. The virus can infect normal cells and undergo replication and expression of viral antigen genes in those cells but cannot produce normal infectious virus. The pharmaceutical is for prophylactic or therapeutic use in generating an immune response in a subject infected therewith. Where the non-retroviral virus is a herpes simplex virus eg HSV-1 or HSV-2, the defect can be in the glycoprotein gH gene. Vaccines and therapeutic pharmaceuticals are provided especially for epithelial, oral, vaginal and nasal administration. Also provided is use of a mutant based on HSV-1 for the preparation of a pharmaceutical for prophylactic or therapeutic use in generating an immune response in a subject against type-2 HSV infection.Type: GrantFiled: March 21, 1994Date of Patent: November 17, 1998Assignee: Cantab Pharmaceuticals Research LimitedInventors: Stephen Charles Inglis, Michael Edward Griffith Boursnell, Anthony Charles Minson
-
Patent number: 5665362Abstract: A mutant virus for use as a vaccine, wherein the genome of the virus is defective in respect of a gene essential for the production of infectious virus. In one aspect the mutant virus is capable of protecting a susceptible species immunized therewith against infection by the corresponding wild-type virus. In another aspect, the mutant virus acts as a vector for an immunogenic protein derived from a pathogen and which is encoded by foreign DNA incorporated in the mutant virus. The mutant virus can be produced in a recombinant host cell which expresses a gene complementing the defect. The mutant virus is preferably infectious for the host to be protected, but the defective gene allows expression in the infected host of at least some of the vital genes, which can provoke a cell-mediated immune response.Type: GrantFiled: February 7, 1995Date of Patent: September 9, 1997Assignee: Cantab Pharmaceuticals Research LimitedInventors: Stephen Charles Inglis, Michael Edward Griffith Boursnell, Anthony Charles Minson